Hello, everyone. The forecast suggests a chilly day here on the Pharmalot corporate campus, but it is December, after all, so who can be surprised? Of course, this calls for a warm cup of stimulation or two, so while we prepare those and some short people for the ride to the schoolhouse, here are a few items to warm you up. Hope your day goes well...
Glaxo Takes A 19 Percent Stake In Aspen (Reuters)
Pfizer And Protalix Strike Deal On Gaucher's Drug (Associated Press)
NARB Denies Novartis Appeal For Excedrin Claims (Drug Store News)
Pfizer To Start Generic Sales In Japan In 2011 (Bloomberg News)
Pfizer And Cipla Discuss Supply Pact (Reuters)
1 Comment
Re: Pfizer to start generic sales...
You have to wonder how many (if any) ANDAs have already been filed for these Pfizer products for sale within the US.
When it is another company looking to get a piece of the pie- an ANDA is filed and the approval results in a generic. When the major manufacturer files an ANDA it- it is called "adjustments" and the product keeps "branded drug" pricing & status.
Where it gets interesting is in looking at the innovator numbers (AUC0, T-1/2, cmax, etc.) whether they be compared to a competitor's ANDA or as compared to the major manufacturers own ANDA. Not going to elaborate- but come on. Bioewhatency? That's all I'm comfortable saying about that.
At least in Japan they're going to call them generics.